Clinical trial XL184-313
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Exelixis |
EudraCT Identifier | 2018-004567-31 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03937219 |
Inclusion criteria | Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment. |
Last update |